{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:11:32Z","timestamp":1791648692245,"version":"4.3.4"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007059","name":"Univerzita Palack\u00e9ho v Olomouci","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007059","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.cbi.2014.06.009","type":"journal-article","created":{"date-parts":[[2014,6,19]],"date-time":"2014-06-19T13:32:55Z","timestamp":1403184775000},"page":"203-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells"],"prefix":"10.1016","volume":"219","author":[{"given":"Petr","family":"Kosztyu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romana","family":"Bukvova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Dolezel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Mlejnek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2014.06.009_b0005","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/315758a0","article-title":"Structural organization of the bcr gene and its role in the Ph\u2032 translocation","volume":"315","author":"Heisterkamp","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.cbi.2014.06.009_b0010","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.cbi.2014.06.009_b0015","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"28","author":"Kantarjian","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cbi.2014.06.009_b0020","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"issue":"Suppl. 2","key":"10.1016\/j.cbi.2014.06.009_b0025","first-page":"S11","article-title":"Resistance and relapse with imatinib in CML: causes and consequences","volume":"6","author":"Deininge","year":"2008","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.cbi.2014.06.009_b0030","doi-asserted-by":"crossref","first-page":"7389","DOI":"10.1038\/sj.onc.1206942","article-title":"Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias","volume":"22","author":"Shah","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.cbi.2014.06.009_b0035","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.cbi.2014.06.009_b0040","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1101\/gr.184901","article-title":"The human ATP-binding cassette (ABC) transporter superfamily","volume":"11","author":"Dean","year":"2001","journal-title":"Genome Res."},{"key":"10.1016\/j.cbi.2014.06.009_b0045","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cbi.2014.06.009_b0050","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ctrv.2009.08.004","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors","volume":"35","author":"Van Erp","year":"2009","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.cbi.2014.06.009_b0055","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1124\/dmd.109.031302","article-title":"Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib","volume":"38","author":"Dohse","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.cbi.2014.06.009_b0060","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models","volume":"101","author":"Mahon","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.cbi.2014.06.009_b0065","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/sj.leu.2403257","article-title":"P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate","volume":"18","author":"Illmer","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.cbi.2014.06.009_b0070","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.exphem.2005.03.014","article-title":"RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines","volume":"33","author":"Rumpold","year":"2005","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.cbi.2014.06.009_b0075","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1182\/blood-2004-04-1398","article-title":"Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)\/ABCG2 drug pump","volume":"104","author":"Burger","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.cbi.2014.06.009_b0080","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/sj.leu.2404638","article-title":"Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells","volume":"21","author":"Brendel","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.cbi.2014.06.009_b0085","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1182\/blood-2003-01-0083","article-title":"Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro","volume":"102","author":"Ferrao","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.cbi.2014.06.009_b0090","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1038\/sj.leu.2403853","article-title":"Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia","volume":"19","author":"Zong","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.cbi.2014.06.009_b0095","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1182\/blood-2006-02-003145","article-title":"Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate","volume":"108","author":"Jordanides","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cbi.2014.06.009_b0100","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s11095-007-9376-3","article-title":"Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells","volume":"25","author":"Hirayama","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.cbi.2014.06.009_b0105","doi-asserted-by":"crossref","first-page":"9809","DOI":"10.1158\/0008-5472.CAN-08-1008","article-title":"Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression","volume":"68","author":"Mahon","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.cbi.2014.06.009_b0110","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/leu.2009.166","article-title":"Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters","volume":"23","author":"Davies","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.cbi.2014.06.009_b0115","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1476-5381.2009.00383.x","article-title":"Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties","volume":"158","author":"Heged\u0171s","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.cbi.2014.06.009_b0120","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.phrs.2012.10.012","article-title":"Can P-glycoprotein mediate resistance to nilotinib in human leukaemia cells?","volume":"67","author":"Kosztyu","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.cbi.2014.06.009_b0125","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1471-2407-8-51","article-title":"Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML)","volume":"8","author":"Tang","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cbi.2014.06.009_b0130","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/jcp.22775","article-title":"P-glycoprotein mediates resistance to A3 adenosine receptor agonist 2-chloro-N6-(3-iodobenzyl)-adenosine-5\u2032-N-methyluronamide in human leukemia cells","volume":"227","author":"Mlejnek","year":"2012","journal-title":"J. Cell Physiol."},{"key":"10.1016\/j.cbi.2014.06.009_b0135","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1158\/0008-5472.CAN-04-3303","article-title":"Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib)","volume":"65","author":"Elkind","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.cbi.2014.06.009_b0140","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1182\/blood-2004-04-1566","article-title":"Increased expression of the Abcg2 transporter during erythroid maturation plays a role in decreasing cellular protoporphyrin IX levels","volume":"105","author":"Zhou","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cbi.2014.06.009_b0145","doi-asserted-by":"crossref","first-page":"21493","DOI":"10.1016\/S0021-9258(20)80566-3","article-title":"Fluorescent cellular indicators are extruded by the multidrug resistance protein","volume":"268","author":"Homolya","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cbi.2014.06.009_b0150","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/0005-2736(94)90190-2","article-title":"Calcein accumulation as a fluorometric functional assay of the multidrug transporter","volume":"1191","author":"Holl\u00f3","year":"1994","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.cbi.2014.06.009_b0155","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/0008-5472.CAN-03-3298","article-title":"Pheophorbide a is a specific probe for ABCG2 function and inhibition","volume":"64","author":"Robey","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.cbi.2014.06.009_b0160","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.cbi.2014.06.009_b0165","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/(SICI)1097-4644(20000401)77:1<6::AID-JCB2>3.0.CO;2-3","article-title":"Induction of apoptosis in HL-60 cells by N6-benzyladenosine","volume":"77","author":"Mlejnek","year":"2000","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.cbi.2014.06.009_b0170","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.talanta.2010.11.028","article-title":"A non-radioactive assay for precise determination of intracellular levels of imatinib and its main metabolite in Bcr-Abl positive cells","volume":"83","author":"Mlejnek","year":"2011","journal-title":"Talanta"},{"key":"10.1016\/j.cbi.2014.06.009_b0175","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.jchromb.2011.05.008","article-title":"Assay for determination of daunorubicin in cancer cells with multidrug resistance phenotype","volume":"879","author":"Krumpochova","year":"2011","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.cbi.2014.06.009_b0180","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0005-2736(99)00166-2","article-title":"Insights into the structure and substrate interactions of the P-glycoprotein multidrug transporter from spectroscopic studies","volume":"1461","author":"Sharom","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.cbi.2014.06.009_b0185","doi-asserted-by":"crossref","first-page":"7468","DOI":"10.1038\/sj.onc.1206948","article-title":"P-glycoprotein: from genomics to mechanism","volume":"22","author":"Ambudkar","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.cbi.2014.06.009_b0190","doi-asserted-by":"crossref","first-page":"e22429","DOI":"10.1371\/journal.pone.0022429","article-title":"Sensitive and specific fluorescent probes for functional analysis of the three major types of mammalian ABC transporters","volume":"6","author":"Lebedeva","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.cbi.2014.06.009_b0195","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00249-009-0555-5","article-title":"On a biophysical and mathematical model of Pgp-mediated multidrug resistance. understanding the \u201cspace-time\u201d dimension of MDR","volume":"39","author":"Panagiotopoulou","year":"2010","journal-title":"Eur. Biophys. J."},{"key":"10.1016\/j.cbi.2014.06.009_b0200","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1042\/bse0500161","article-title":"The P-glycoprotein multidrug transporter","volume":"50","author":"Sharom","year":"2011","journal-title":"Essays Biochem."},{"key":"10.1016\/j.cbi.2014.06.009_b0205","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1021\/cr9000226","article-title":"ABC efflux pump-based resistance to chemotherapy drugs","volume":"109","author":"Eckford","year":"2009","journal-title":"Chem. Rev."},{"key":"10.1016\/j.cbi.2014.06.009_b0210","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/jpet.103.053298","article-title":"Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3)","volume":"308","author":"Jonker","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.cbi.2014.06.009_b0215","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00277-010-1142-7","article-title":"Interactions of N-desmethyl imatinib, an active metabolite of imatinib, with P-glycoprotein in human leukemia cells","volume":"90","author":"Mlejnek","year":"2011","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.cbi.2014.06.009_b0220","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1748-1716.2010.02087.x","article-title":"Induction of apoptosis by A3 adenosine receptor agonist N-(3-iodobenzyl)-adenosine-5\u2032-N-methylcarboxamide in human leukaemia cells: a possible involvement of intracellular mechanism","volume":"199","author":"Mlejnek","year":"2010","journal-title":"Acta Physiol."},{"key":"10.1016\/j.cbi.2014.06.009_b0225","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1158\/1535-7163.1119.3.9","article-title":"Gefitinib reverses breast cancer resistance protein-mediated drug resistance","volume":"3","author":"Yanase","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.cbi.2014.06.009_b0230","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1182\/blood-2002-01-0271","article-title":"Low levels of ABCG2 expression in adult AML blast samples","volume":"100","author":"Abbott","year":"2002","journal-title":"Blood"}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279714001884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279714001884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T13:33:47Z","timestamp":1757856827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279714001884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":46,"alternative-id":["S0009279714001884"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2014.06.009","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2014.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}